We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Dried Blood Spot Sampling Used for HbA1c Measurement

By LabMedica International staff writers
Posted on 28 Sep 2015
Print article
Indiko Plus Clinical and Specialty Chemistry fully automated analyzer
Indiko Plus Clinical and Specialty Chemistry fully automated analyzer (Photo courtesy of THERMO FISHER SCIENTIFIC)
The use of dried blood spot (DBS) sampling is an alternative to traditional venous blood collection, and particularly useful for people living in rural and remote areas, and for those who are infirm, house-bound or time-poor.

Glycated hemoglobin (HbA1c) is a biomarker that is fundamental for the diagnosis of diabetes and for monitoring glycemic control and traditionally its measurement depends on venipuncture, and on processing, transportation and storage of whole blood (WB) samples, which can be logistically challenging.

Scientists at The Australian National University (Canberra, Australia) collected venous and capillary blood samples from 115 adult participants. After proper instruction, each participant punctured his/her own finger and collected capillary blood samples on pieces of a proprietary cellulose filter paper. Each filter paper was subsequently placed inside a breathable envelope, stored at room temperature, and processed on the same day (D0), four (D4), seven (D7) and fourteen (D14) days after collection.

HbA1c levels were measured in duplicates/triplicates in whole venous blood (WB), capillary blood (capDBS) and venous blood placed on the matrix paper (venDBS) and determined by a direct turbidimetric inhibition immunoassay that determines HbA1c as a percentage of total hemoglobin (%HbA1c). Assays were performed on an Indiko Plus (Thermo Fisher Scientific; Waltham, MA USA) automated biochemistry analyzer, and results were reported as %HbA1c National Glycohemoglobin Standardization Program (NGSP) values.

Eleven and 56 patients had type 1 and type 2 diabetes mellitus, respectively. Overall mean whole blood HbA1c levels were 6.22 ± 1.11%, 5.41 ± 0.35% for participants without diabetes, 7.80 ± 0.81% for volunteers with type 1 diabetes, and 6.61 ± 1.11% among individuals with type 2 diabetes. Mean ± SD capillary DBS (capDBS) levels of HbA1c were 6.62 ± 1.16% when measured on D0, 6.92 ± 1.32% on D4, 6.85 ± 1.29% on D7, and 6.62 ± 1.44% on D14. Venous DBS samples ranged from 6.72 ± 1.20% on D0 to 7.36 ± 1.47% on D7. Results from capDBS and venDBS showed high correlation and agreement to WB results, except for results from D14 samples.

The authors concluded the measurement of HbA1c from DBS samples provided results that were comparable to results from WB samples, if measured up to seven days after collection. Intra-assay coefficients of variation were low, results were in agreement with the gold-standard, and prediction intervals were clinically acceptable. The measurement of HbA1c through DBS sampling may be considered in situations where traditional venipuncture is not available. The study was published on July 8, 2015, in the journal BMC Clinical Pathology.

Related Links:

The Australian National University
Thermo Fisher Scientific 


New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Troponin T QC
Troponin T Quality Control
New
MTHFR Mutation Test
REALQUALITY THROMBO MTHFR
New
Mumps Virus Test
ReQuest Mumps IgG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.